| Recruiting | Recurrent Visceral Leishmaniasis in HIV Co-Infection NCT07487350 | Institute of Tropical Medicine, Belgium | — |
| Active Not Recruiting | Human Bioequivalence Study of Liposomal Amphotericin B for Injection NCT06983665 | Sichuan Huiyu Pharmaceutical Co., Ltd | N/A |
| Completed | Human Bioequivalence Study of Amphotericin B Liposome for Injection NCT06977490 | Sichuan Huiyu Pharmaceutical Co., Ltd | N/A |
| Terminated | Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study NCT06118749 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Recruiting | Clinical Prognostic Score to Predict Relapse in VL NCT05602610 | Institute of Tropical Medicine, Belgium | — |
| Unknown | Evaluation to Assess the Usability of rK28 for the Diagnosis of Visceral Leishmaniasis in Kenya NCT05386875 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Active Not Recruiting | A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis NCT04342715 | University of York | — |
| Unknown | Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure NCT05426577 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Completed | Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects NCT03929016 | Drugs for Neglected Diseases | Phase 1 |
| Completed | LAMP Assay for the Diagnosis of Visceral Leishmaniasis NCT04003532 | Prof. Dawit Wolday | — |
| Completed | Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition NCT03636659 | Aurobindo Pharma Ltd | Phase 1 |
| Completed | Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Easte NCT03129646 | Drugs for Neglected Diseases | Phase 3 |
| Completed | Improved Case Detection and Vector Control for Visceral Leishmaniasis NCT03269006 | International Centre for Diarrhoeal Disease Research, Bangladesh | N/A |
| Terminated | Asymptomatic Leishmania Infection in HIV Patients NCT02839603 | Institute of Tropical Medicine, Belgium | — |
| Completed | Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children NCT02431143 | Drugs for Neglected Diseases | Phase 2 |
| Completed | Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of NCT02011958 | Drugs for Neglected Diseases | Phase 3 |
| Unknown | Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis NCT01566552 | Banaras Hindu University | Phase 4 |
| Completed | Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers NCT02071758 | Access to Advanced Health Institute (AAHI) | Phase 1 |
| Terminated | Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan NCT01980199 | Drugs for Neglected Diseases | Phase 2 |
| Completed | Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fev NCT01766830 | University Hospital, Geneva | N/A |
| Terminated | Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil NCT01310738 | University of Brasilia | Phase 4 |
| Completed | An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in NCT01328457 | PATH | N/A |
| Completed | Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for NCT01122771 | Drugs for Neglected Diseases | Phase 3 |
| Unknown | Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine NCT01138956 | Hospital Universitário Professor Edgard Santos | N/A |
| Completed | Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia NCT02148822 | Instituto de Salud Carlos III | — |
| Completed | A Community Trial for Visceral Leishmaniasis (VL) NCT01069198 | International Centre for Diarrhoeal Disease Research, Bangladesh | N/A |
| Terminated | Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Pa NCT00832208 | Drugs for Neglected Diseases | Phase 2 |
| Completed | Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis NCT00696969 | Drugs for Neglected Diseases | Phase 3 |
| Completed | Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis NCT00628719 | Banaras Hindu University | Phase 3 |
| Completed | An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leish NCT00629031 | Banaras Hindu University | Phase 3 |
| Completed | Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar NCT00371995 | Banaras Hindu University | Phase 2 |
| Completed | Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmanias NCT00604955 | PATH | Phase 4 |
| Completed | Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children NCT01032187 | University of Brasilia | Phase 4 |
| Completed | A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Banglad NCT01240473 | International Centre for Diarrhoeal Disease Research, Bangladesh | N/A |
| Completed | Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in Indi NCT00486382 | Access to Advanced Health Institute (AAHI) | Phase 1 |
| Completed | A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Aza NCT00497601 | Banaras Hindu University | Phase 2 |
| Completed | Combination Chemotherapy for the Treatment of Indian Kala-Azar NCT00370825 | Banaras Hindu University | Phase 2 |
| Completed | Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Ka NCT00318721 | London School of Hygiene and Tropical Medicine | N/A |
| Completed | Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leish NCT00255567 | Drugs for Neglected Diseases | Phase 3 |
| Completed | Immunogenetics of Visceral Leishmaniasis NCT00342823 | National Human Genome Research Institute (NHGRI) | — |
| Completed | Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis NCT00216346 | PATH | Phase 3 |
| Completed | Amphotericin B Treatment in Visceral Leishmaniasis NCT00310505 | Banaras Hindu University | N/A |